Next Generation News and Research

RSS

Trintech first-quarter revenues up 9% to $8.5 million

Trintech Group Plc, a leading provider of integrated financial governance, risk management and compliance (GRC) solutions for commercial, financial and healthcare markets, today announced its first quarter 2011 financial results. Following the sale of its healthcare business to The Advisory Board Company on April 1, 2010, Trintech is required to present its financial results on a continuing and discontinued basis.

26 May 2010

T2 Biosystems raises $15 million to accelerate development of next generation diagnostic platform

T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.

25 May 2010

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.

25 May 2010

Hospitalar Welch Allyn to feature electronic connected solutions for frontline caregivers in Latin America

Hospitalar—Welch Allyn, a leading global manufacturer of frontline medical products and solutions, is reconfirming its commitment to caregivers in Latin America with innovative solutions to healthcare issues that are unique to the region. In March 2009 the company acquired MD International (MDI), now Welch Allyn Latin America, and has since gained significant market share in South and Central America, Mexico and the Caribbean thanks to strong relationships with large distribution and manufacturer partners.

25 May 2010

RainDance Technologies increases commercial activities in Europe with series of technology seminars

RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, today announced it is increasing its commercial activities in Europe beginning with a series of technology seminars during the week of 24 May 2010.

25 May 2010

Joint research by UB and CDC could lead to new generation of antiviral medicines

Future pandemics of seasonal flu, H1N1 and other drug-resistant viruses may be thwarted by a potent, immune-boosting payload that is effectively delivered to cells by gold nanorods, report scientists at the University at Buffalo and the U.S. Centers for Disease Control and Prevention. The work is published in the current issue of the Proceedings of the National Academy of Sciences.

25 May 2010

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Boston Scientific Corporation today announced CE Mark and U.S. Food and Drug Administration approval of its NC Quantum Apex PTCA Dilatation Balloon Catheter. The Company plans to launch the product in European markets this week and in the U.S. next month.

25 May 2010

Northrop Grumman begins delivery of critical assay technology to DHS for homeland defense applications

Northrop Grumman Corporation has begun deliveries of critical assay technology to the U.S. Department of Homeland Security as part of the company's BioWatch Gen-3 contract to develop a new generation of biological detectors for homeland defense applications.

25 May 2010

Volcano to highlight extensive pipeline of imaging and therapy products at EuroPCR 2010

Volcano Corporation announced today the company's plans to highlight its new product launches, presence in live cases, and participation in late breaking trials during EuroPCR from May 25 – 28 in Paris.

24 May 2010

Researchers look for new ways of targeting Alzheimer's disease

The Alzheimer's Association released a report on Wednesday, May 19, predicting that the cost of Alzheimer's disease over the next 40 years would reach $20 trillion if newer treatments are not on the horizon.

24 May 2010

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

21 May 2010

New England Peptide launches NEPTune line of custom proteomics reagents

New England Peptide (NEP) today introduced NEPTune TM, a new proprietary line of custom proteomics reagents to help its customers to quickly and inexpensively maximize biomarker assay development and produce consistent results.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

As US policymakers consider scaling back on its historic initiative to fight AIDS around the world and downsizing goals to combat tuberculosis, next-generation treatment and prevention strategies to significantly reduce the spread of HIV/AIDS and tuberculosis are now imminent. New science can dramatically change the trajectory of both deadly epidemics, according to a special new issue of the journal Clinical Infectious Diseases.

21 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Studies identify new chemical compounds that could lead to development of new malaria drugs

Researchers have identified thousands of chemical compounds that could be used to develop new malaria drugs, two studies published in the journal Nature on Wednesday show, the Wall Street Journal reports.

21 May 2010

St. Jude Medical to acquire LightLab for $90M in cash

St. Jude Medical, Inc., a global medical device company, and LightLab Imaging, Inc. today announced a definitive agreement under which St. Jude Medical will acquire LightLab, a subsidiary of Goodman Co., Ltd. for approximately $90 million in cash.

20 May 2010

Health care high school to open in Chicago

Crain's Chicago Business reports that, in the fall, the city will open its "first charter high school specializing in health care, a move local hospitals hope will help relieve chronic workforce shortages. ... Juniors and seniors will be able to earn credits by shadowing hospital workers and interning as assistant nurses and in other professions."

20 May 2010

Curis announces inclusion in NASDAQ Biotechnology Index

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.

19 May 2010

PrimeWire PRESTIGE Pressure Guide Wire receives 510(k) clearance, CE Mark approval

Volcano Corporation announced today it received both 510(k) clearance and CE Mark approval for its PrimeWire PRESTIGE Pressure Guide Wire for use with patients who have both single-vessel and multi-vessel disease. This next generation pressure wire is compatible with Volcano's full suite of integrated multi-modality consoles and stand-alone physiology systems as well as various hemodynamic monitoring systems.

19 May 2010

Next Generation News and Research

Trintech first-quarter revenues up 9% to $8.5 million

T2 Biosystems raises $15 million to accelerate development of next generation diagnostic platform

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Hospitalar Welch Allyn to feature electronic connected solutions for frontline caregivers in Latin America

RainDance Technologies increases commercial activities in Europe with series of technology seminars

Joint research by UB and CDC could lead to new generation of antiviral medicines

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Northrop Grumman begins delivery of critical assay technology to DHS for homeland defense applications

Volcano to highlight extensive pipeline of imaging and therapy products at EuroPCR 2010

Researchers look for new ways of targeting Alzheimer's disease

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

New England Peptide launches NEPTune line of custom proteomics reagents

New therapy program serves as foundation for ongoing clinical development

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Studies identify new chemical compounds that could lead to development of new malaria drugs

St. Jude Medical to acquire LightLab for $90M in cash

Health care high school to open in Chicago

Curis announces inclusion in NASDAQ Biotechnology Index

PrimeWire PRESTIGE Pressure Guide Wire receives 510(k) clearance, CE Mark approval

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News